The company has previously been approved to work with psilocybin, LSD, MDMA and ketamine and their Dealer’s Licence allows Numinus to possess, test, produce, assemble, sell, export and deliver a range of psychedelic compounds.Article content
Recognizing that these substances have long had traditional and ceremonial uses, Payton Nyquvest, CEO and founder of Numinus, said the latest amendments “honour and build on those practices while allowing us to do novel clinical research and deepen the body of scientific data for scaled development and greater public access to much-needed therapies.”
In January, Numinus was included in a Health Canada list of companies that can supply psilocybin to approved applicants through the Special Access Program .like psilocybin- and MDMA-assisted therapy, on a case-by-case basis.Article contentSpencer Hawkswell, the CEO of TheraPsil, a B.C.-based non-profit that helps Canadians access psychedelic-assisted psychotherapy, previously told“We’ve been yelling in the streets for the last few years that this is too little too late. But it truly is.